Bloom lab
@jbloomlab.bsky.social
14K followers 820 following 320 posts
Lab studying molecular evolution of proteins and viruses. Affiliated with Fred Hutch & HHMI. https://jbloomlab.org/
Posts Media Videos Starter Packs
jbloomlab.bsky.social
Finally, we plan to repeat this effort in ~6 months prior to next vaccine strain selection. If you have sera cohorts that you think would be well suited for this type of study and are potentially interesting in collaborating, please feel free to reach out.
jbloomlab.bsky.social
Thanks to @ckikawa.bsky.social & @huddlej.bsky.social for leading study, also: Andrea Loes, Sam Turner, Jover Lee, Ian Barr, Ben Cowling, Jan Englund, Alex Greninger, Ruth Harvey, H Hasegawa, Faith Ho, K Lacombe, Nancy Leung, Nicola Lewis, Heidi Peck, Shinji Watanabe, Derek Smith, Trevor Bedford
jbloomlab.bsky.social
Many more analyses are possible w these data. But we have made all data & code available now at github.com/jbloomlab/fl...

Reason is to provide near real-time titer data that can be leveraged by scientific community for real-time decisions like vaccine strain selection.
GitHub - jbloomlab/flu-seqneut-2025
Contribute to jbloomlab/flu-seqneut-2025 development by creating an account on GitHub.
github.com
jbloomlab.bsky.social
Above visualizations just scratch surface of data: there is tremendous heterogeneity across sera from different individuals not easily summarized by median/mean.

Indeed, we previously found this heterogeneity may be important for influenza evolution: elifesciences.org/reviewed-pre...
jbloomlab.bsky.social
Working w @huddlej.bsky.social & Trevor Bedford, we mapped neutralization titers on interactive Nextstrain trees to visualize neutralization across subclades and natural mutations.

See:

nextstrain.org/groups/blab/...

nextstrain.org/groups/blab/...
auspice
nextstrain.org
jbloomlab.bsky.social
We then measured how 188 human sera recently collected at four different sites neutralized all 140 influenza strains in library.

Titers are summarized below; can be examined interactively at jbloomlab.github.io/flu-seqneut-... & jbloomlab.github.io/flu-seqneut-...
jbloomlab.bsky.social
In spring of 2025, we designed library of naturally occurring human seasonal influenza strains that represented diversity of available sequences at that time; this library continues to cover most sequenced diversity of H3N2 and H1N1 hemagglutinin today.
jbloomlab.bsky.social
To do this, we used sequencing-based neutralization assays that measure many neutralization curves simultaneously (journals.asm.org/doi/10.1128/... & elifesciences.org/reviewed-pre...)

Approach enabled one grad student (@ckikawa.bsky.social) to measure ~26,000 neutralization curves in ~5 months.
jbloomlab.bsky.social
But because it takes time to perform experiments, measurement of how current strains are neutralized by human serum antibodies can lag timeline for vaccine strain selection.

Our goal was to use new approach to characterize human antibody landscape at scale in near real-time.
jbloomlab.bsky.social
As background, seasonal influenza evolves to erode antibody immunity.

Viruses w more antibody escape spread in human population & people more likely to be infected by strains their antibodies neutralize less well.

Vaccine updated bi-annually to keep pace w viral evolution.
jbloomlab.bsky.social
Data in interactive form at dms-vep.org/CHIKV-181-25...

Thanks to Xiaohui Ju for leading study

Special thanks to @msdiamondlab.bsky.social for help
Also Will Hannon, Caelan Radford, Brendan Larsen, Daved Fremont, Ofer Zimmerman, Tomasz Kaszuba, Chris Nelson, Israel Baltazar-Perez, Samantha Nelson
jbloomlab.bsky.social
Overall, these results shed light on how Chikungunya virus naturally infects cells from highly diverse species.

Sequence-function information can aid in immunogen engineering, and loss-of-tropism mutants could be useful in vaccines as well.
jbloomlab.bsky.social
After using pseudoviruses & reporter particles to show mutations *loss* of function, we engineered into Chikungunya virus: mutants lost ability to infect human or mosquito cells.

So we reduced natural tropism for both human & mosquito cells to just one type of cell.
jbloomlab.bsky.social
We next used non-replicative single-cycle alphavirus reporter particles (which provide another safe way to study mutations) to validate that mutations identified in deep mutational scanning indeed specifically impaired entry in human or mosquito cells only.
jbloomlab.bsky.social
Sites where mutations specifically impair entry in 293T-MXRA8 cells mostly at MXRA8 binding interface.

We also find sites where mutations specifically impair entry in C6/36 cells. Although mosquito receptor unknown, we hypothesize these sites at its binding interface.
jbloomlab.bsky.social
Most mutations similarly affect entry in all three cells, but some have cell-specific effects.

For instance, mutations at E2 site 119 are generally tolerated in C6/36 and 293T-TIM1 cells, but deleterious in 293T-MXRA8 cells.

(See dms-vep.org/CHIKV-181-25... for interactive plot.)
jbloomlab.bsky.social
We then measured how mutations affect entry in two other cells: the mosquito cell-line C6/36, and 293T cells expressing TIM1 which enables envelope protein independent cell binding by virion associated phosphatidylserine.
jbloomlab.bsky.social
We first measured how mutations affect entry in 293T cells expressing human receptor MXRA8.

Below is constraint mapped on structure; see dms-vep.org/CHIKV-181-25... for interactive heatmap of these data.
jbloomlab.bsky.social
We used pseudovirus deep mutational scanning to measure effects of all mutations to envelope proteins in context of single-cycle pseudotyped particles that provide a safe way to study viral protein mutations outside context of fully infectious virus.
jbloomlab.bsky.social
Chikungunya virus enters cell using its envelope proteins, which are also target of neutralizing antibodies and vaccine design.

A receptor for these viral proteins in mammalian cells is the protein MXRA8, but receptor in mosquito cells is unknown.
jbloomlab.bsky.social
As background, Chikungunya virus has transmission cycle that involves infecting both mosquitoes & humans or other primates.

Infection can cause fever and severe joint pain in humans.

Outbreaks are growing due to expanding mosquito range: www.nytimes.com/2025/08/19/h...
jbloomlab.bsky.social
In new study led by Xiaohui Ju, we define how mutations to Chikungunya virus envelope proteins affect entry in human vs mosquito cells.

Sheds light on functional constraints & enables us to make loss-of-tropism mutants, which could be of use for vaccines.

www.biorxiv.org/content/10.1...
Determinants of human versus mosquito cell entry by the Chikungunya virus envelope proteins
Chikungunya virus (CHIKV) infects both humans and mosquitoes during its transmission cycle. How the virus’s envelope proteins mediate entry in cells from such different species is unclear. MXRA8 is a ...
www.biorxiv.org
jbloomlab.bsky.social
All data available in interactive form at dms-vep.org/SARS-CoV-2_K... and we encourage exploration of that site.

Study led by the incomparable @bdadonaite.bsky.social, w help from Sheri Harari, Brendan Larsen, Lucas Kampman, Alex Harteloo, Anna Elias-Warren, & Helen Chu.
Pseudovirus deep mutational scanning of SARS-CoV-2 spike from KP.3.1.1 strain
Data, figures, and analysis for KP.3.1.1 spike .
dms-vep.org
jbloomlab.bsky.social
Finally, we measured how mutations affect neutralization by three relevant monoclonal antibodies. As shown below, all antibodies adversely affected by mutating site 505 which fortunately remains highly constrained for ACE2 binding. We discuss this interesting site more in preprint.